Search Clinical Trials
583,298 trials
ID
Status
Phase
Title
Sponsor
NCT07571161
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseEli Lilly and CompanyNot Yet RecruitingPhase 3
NCT07571161Not Yet Recruiting
Phase 3
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired...Eli Lilly and Company
NCT07571837
Modulation of Periapical Inflammation Following Nano-sized Intracanal Medication. A Randomized Controlled Clinical TrialAl-Azhar UniversityRecruitingNot Applicable
NCT07571837Recruiting
Not Applicable
Modulation of Periapical Inflammation Following Nano-sized Intracanal Medication...Al-Azhar University
NCT07570836
Safety and Preliminary Efficacy of hUCMSC-EVs in Interstitial Lung DiseaseShanghai Zhongshan HospitalNot Yet RecruitingPhase 1
NCT07570836Not Yet Recruiting
Phase 1
Safety and Preliminary Efficacy of hUCMSC-EVs in Interstitial Lung DiseaseShanghai Zhongshan Hospit...
NCT07570862
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus NephritisFate TherapeuticsNot Yet RecruitingPhase 2
NCT07570862Not Yet Recruiting
Phase 2
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Neph...Fate Therapeutics
NCT07569042
A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed GlioblastomaNovelwise Pharmaceutical CorporationRecruitingPhase 1
NCT07569042Recruiting
Phase 1
A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Ne...Novelwise Pharmaceutical...
NCT07569757
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.Not Yet RecruitingPhase 3
NCT07569757Not Yet Recruiting
Phase 3
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaChia Tai Tianqing Pharmac...
NCT07569341
Validation of the Classification for Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal MetastasesLinkoeping UniversityCompleted
NCT07569341Completed
—
Validation of the Classification for Resectability and Ablatability Criteria for...Linkoeping University
NCT07570355
Pterygopalatine Ganglion Stimulation for the Treatment of Geographic AtrophyShanghai Institute of Acupuncture, Moxibustion and MeridianNot Yet RecruitingNot Applicable
NCT07570355Not Yet Recruiting
Not Applicable
Pterygopalatine Ganglion Stimulation for the Treatment of Geographic AtrophyShanghai Institute of Acu...
NCT07570511
Point of Care Testing INR in Antiphospholipid SyndromeCentral Hospital, Nancy, FranceNot Yet RecruitingNot Applicable
NCT07570511Not Yet Recruiting
Not Applicable
Point of Care Testing INR in Antiphospholipid SyndromeCentral Hospital, Nancy,...
NCT07571343
Fueling Labor: Protein Supplementation for Intrapartum Glucose ControlMedical College of WisconsinNot Yet RecruitingNot Applicable
NCT07571343Not Yet Recruiting
Not Applicable
Fueling Labor: Protein Supplementation for Intrapartum Glucose ControlMedical College of Wiscon...
NCT07569458
Online Personalized Psychological Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE)Aalborg University HospitalRecruitingNot Applicable
NCT07569458Recruiting
Not Applicable
Online Personalized Psychological Intervention for Patients With Heart Disease a...Aalborg University Hospit...
NCT07569211
Simplified HCV Integrated Management Model in Methadone Clinics in UkraineThe Western-Eastern European Partnership Initiative on HIV, Viral Hepatitis and TBCompletedNot Applicable
NCT07569211Completed
Not Applicable
Simplified HCV Integrated Management Model in Methadone Clinics in UkraineThe Western-Eastern Europ...
NCT07570849
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic CholangiocarcinomaShanghai Zhongshan HospitalRecruitingPhase 2
NCT07570849Recruiting
Phase 2
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment f...Shanghai Zhongshan Hospit...
NCT07569068
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ AdenocarcinomaRuijin HospitalRecruitingPhase 2
NCT07569068Recruiting
Phase 2
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Posit...Ruijin Hospital
NCT07569770
Comparing High-Protein and Low-Protein Multi-Ingredient Supplements for Body Composition and Performance in Elite Rugby PlayersUniversity of TaipeiCompletedNot Applicable
NCT07569770Completed
Not Applicable
Comparing High-Protein and Low-Protein Multi-Ingredient Supplements for Body Com...University of Taipei
NCT07571863
Radiographic And Histomorphometric Assessment Following Alveolar Ridge Preservation Using Chitosan Gel Versus Normal Socket Healing In Posterior Maxillary and Mandibular RegionCairo UniversityCompletedNot Applicable
NCT07571863Completed
Not Applicable
Radiographic And Histomorphometric Assessment Following Alveolar Ridge Preservat...Cairo University
NCT07568990
Ureteral Access Sheaths in Endoscopic Kidney Stone SurgeryHitit UniversityNot Yet RecruitingNot Applicable
NCT07568990Not Yet Recruiting
Not Applicable
Ureteral Access Sheaths in Endoscopic Kidney Stone SurgeryHitit University
NCT07570914
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver MetastasesTianjin Medical University Cancer Institute and HospitalNot Yet RecruitingPhase 2
NCT07570914Not Yet Recruiting
Phase 2
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitab...Tianjin Medical Universit...
NCT07568847
Improving Hospital-To-Methadone Clinic Connection Using Implementation Support for Patients With Opioid Use DisorderNational Institute on Drug Abuse (NIDA)Not Yet RecruitingNot Applicable
NCT07568847Not Yet Recruiting
Not Applicable
Improving Hospital-To-Methadone Clinic Connection Using Implementation Support f...National Institute on Dru...
Result Breakdown
Not yet recruiting10 (50%)
Recruiting6 (30%)
Completed4 (20%)
not_applicable11 (55%)
Phase 24 (20%)
Phase 32 (10%)
Phase 12 (10%)
Not Specified1 (5%)